US Bancorp
BTAI

US Bancorp’s BioXcel Therapeutics BTAI Stock Holding History

US Bancorp’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1 Hold
1
– – ﹤0.01% 4155
2026
Q1 		$1 Hold
1
– – ﹤0.01% 4163
2025
Q4 		$2 Hold
1
– – ﹤0.01% 4032
2025
Q3 		$3 Hold
1
– – ﹤0.01% 3994
2025
Q2 		$2 Hold
1
– – ﹤0.01% 4152
2025
Q1 		$2 Sell
1
-1
-50% -$4 ﹤0.01% 4180
2024
Q4 		$12 Sell
2
-1,125
-100% -$9.4K ﹤0.01% 4143
2024
Q3 		$11K Sell
1,127
-27
-2% -$363 ﹤0.01% 3340
2024
Q2 		$23.6K Buy
1,154
+27
+2% +$904 ﹤0.01% 2992
2024
Q1 		$50.9K Hold
1,127
– – ﹤0.01% 2682
2023
Q4 		$53.2K Hold
1,127
– – ﹤0.01% 2648
2023
Q3 		$45.6K Buy
1,127
+247
+28% +$25K ﹤0.01% 2493
2023
Q2 		$93.7K Buy
880
+878
+43,900% +$292K ﹤0.01% 2229
2023
Q1 		$616 Hold
2
– – ﹤0.01% 3927
2022
Q4 		$709 Sell
2
-24
-92% -$5.8K ﹤0.01% 3962
2022
Q3 		$5K Sell
26
-12
-32% -$2.79K ﹤0.01% 3575
2022
Q2 		$8K Sell
38
-7
-16% -$1.47K ﹤0.01% 3413
2022
Q1 		$15K Sell
45
-7
-13% -$2.03K ﹤0.01% 3214
2021
Q4 		$17K Sell
52
-14
-21% -$6.01K ﹤0.01% 3191
2021
Q3 		$32K Sell
66
-21
-24% -$9.23K ﹤0.01% 2876
2021
Q2 		$41K Sell
87
-220
-72% -$120K ﹤0.01% 2767
2021
Q1 		$212K Sell
307
-16
-5% -$12.9K ﹤0.01% 1900
2020
Q4 		$238K Buy
323
+24
+8% +$18.7K ﹤0.01% 1800
2020
Q3 		$207K Buy
299
+153
+105% +$115K ﹤0.01% 1754
2020
Q2 		$124K Sell
146
-43
-23% -$28K ﹤0.01% 1992
2020
Q1 		$68K Buy
+189
New +$67.9K ﹤0.01% 2205

Other funds holding BTAI

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

US Bancorp's BTAI Position: Q2 2026 in Review

US Bancorp held its BioXcel Therapeutics (BTAI) position steady in Q2 2026 at 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #4155.

US Bancorp first reported a position in BTAI in Q1 2020 and has held it in 26 quarters since. The position peaked at $238K in Q4 2020. 47 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • US Bancorp held 1 share of BioXcel Therapeutics worth $1 as of Q2 2026.
  • US Bancorp left its BioXcel Therapeutics share count unchanged in Q2 2026.
  • BioXcel Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #4155 holding.
  • US Bancorp first reported a position in BioXcel Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • US Bancorp's BioXcel Therapeutics position peaked at $238K in Q4 2020.
  • 47 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.